Tag Archives: imaging

Identity Theft: The Destructive Course of Behavioral Variant Frontotemporal Dementia

UCSF Neurologist Develops Brain Imaging Strategies for Mapping Disease

Read more

U.S. Food and Drug Administration Approves Amyvid PET Scans

The U.S. Food and Drug Administration (FDA) announced on Friday, April 6 2012, that it has approved the use of Amyvid™ (florbetapir) PET scans for patients being evaluated for Alzheimer’s disease and other causes of cognitive impairment. Amyvid is a radiotracer, or a radioactive imaging agent that is injected intravenously at a very small (“trace”) dose. Amyvid PET scans detect the presence of amyloid plaques, one of the core microscopic features of Alzheimer’s disease. A patient with a significant number of amyloid plaques in their brain is likely to have a “positive” Amyvid scan. Read more

Amyloid Imaging Accurately Differentiates AD and FTD

A new type of PET scan can accurately distinguish between Alzheimer’s disease and frontotemporal dementia

Plaques made of amyloid protein are a defining feature of Alzheimer’s disease (AD) but are not typically seen in frontotemporal dementia (FTD). Unfortunately these plaques have not been able to be definitively identified until after the death of a patient, when tissue collected during an autopsy is analyzed with a microscope. Scientists have been searching for a disease marker that can be seen in living people for both accurate diagnosis and tracking the effectiveness of potential therapies. New research shows a marker developed to detect plaque in the brain may help doctors make a more accurate diagnosis between Alzheimer’s and FTD. Read more